Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared a post on LinkedIn:
”In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:
‘Settling the DOAC Debate in Acute VTE’.
For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.
Here are the most important concepts and the clinical shift this trial brings to our practice:
- Identical Efficacy: Both Apixaban and Rivaroxaban demonstrated an identical ~1% rate of recurrent VTE.
- Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84% reduction in major bleeding.
- The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.
Rivaroxaban requires a high-dose induction phase that is three times longer than Apixaban (21 days vs. 7 days).
I am sharing the presentation here. Please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 00:29Iheanyichukwu Ike: Childhood Anaemia in Nigeria Through an Analysis of the 2018 NDHS
-
Sep 21, 2026, 00:27Nicole De Vita: The Global Burden of Iron Deficiency and Anemia in Women at SABM
-
Sep 21, 2026, 00:25Giuseppe Panuccio: IVUS and OCT Guidance Reduce MACE and Stent Thrombosis in Calcified Coronary Lesions
-
Sep 21, 2026, 00:23Parveen Yograj: Anemia in Older Adults 2026 – Don’t Call It “Just Old Age” and Find the Cause
-
Sep 21, 2026, 00:22Peter A. McCullough: McCullough Protocol Base Spike Detoxification and Oral Anticoagulation for Athletes
-
Sep 21, 2026, 00:20Rolando Claure: Apixaban Shows a More Favorable Benefit Risk Balance in Advanced CKD With AF
-
Sep 21, 2026, 00:14Kathaleen Schnur: HCWP’s Bubble Brigade at the 2026 Unite for Bleeding Disorders Walk
-
Sep 21, 2026, 00:13Amr Abouleish: Jehovah’s Witnesses Announce That Accepting Blood Is a Matter of Personal Conscience
-
Sep 21, 2026, 00:08Oluseyi Victor Owoeye: The Importance of Respecting Clients’ Beliefs, Values, Autonomy, and Human Dignity